{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.04","upperLimit":"0.04","value":"0.04"},{"groupId":"OG001","lowerLimit":"0.04","upperLimit":"0.04","value":"0.04"},{"groupId":"OG002","lowerLimit":"0.03","upperLimit":"0.05","value":"0.04"},{"groupId":"OG003","lowerLimit":"0.02","upperLimit":"0.03","value":"0.02"},{"groupId":"OG004","lowerLimit":"0.02","upperLimit":"0.03","value":"0.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Tmax was defined as the time to maximum concentration of MK-0482 observed in plasma. Blood samples were collected pre-dose and post-dose at designated timepoints to determine Tmax of MK-0482.","dispersionType":"Full Range","groups":[{"description":"Participants were to receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \\[Q3W\\]) for up to 35 cycles (approximately 24 months).","id":"OG000","title":"MK-0482 7.5 mg Q3W"},{"description":"Participants were to receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG001","title":"MK-0482 25 mg Q3W"},{"description":"Participants were to receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG002","title":"MK-0482 75 mg Q3W"},{"description":"Participants were to receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG003","title":"MK-0482 225 mg Q3W"},{"description":"Participants were to receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG004","title":"MK-0482 750 mg Q3W"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study intervention, were compliant with the study procedures, and had available data from at least 1 treatment dose were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Pre-dose and Days 1, 2, 4, 8, and 15 post-dose. Cycle=21 days.","title":"Time to Maximum Concentration (Tmax) of MK-0482","type":"SECONDARY","unitOfMeasure":"Days"}